In Brazil, men with advanced prostate cancer who rely on the public health system often wait months before starting modern first-line therapies. The culprit is not a shortage of drugs, but a reimbursement cap that limits how much hospitals can spend on high-cost oncology medicines within a fixed annual budget. As a result, physicians must triage patients, and many men progress to a more aggressive, castration-resistant stage before treatment begins. This article examines how the cap works, the evidence of delay from a São Paulo cohort, the clinical consequences, and the policy options under debate.

A Reimbursement Cap Slows First-Line Access

The Brazilian Unified Health System (SUS) sets a ceiling for the reimbursement of drugs like abiraterone and enzalutamide, both standard first-line therapies for metastatic castration-sensitive prostate cancer. Hospitals and state-level oncology centers receive a pooled annual budget that must cover all cancer treatments, including these expensive agents. Because the cap is per patient per year, hospitals quickly exhaust their allocation and must ration the remaining months.

Patients prescribed abiraterone or enzalutamide often wait weeks or months before the hospital can secure funding for the next budget cycle or obtain special authorization from the Ministry of Health. In practice, this means many men start bicalutamide, an older androgen blockade drug, or simply wait—while their cancer continues to grow. No formal wait-time guarantee exists in the SUS for first-line prostate cancer therapy.

Real-world data from a cohort of 1,200 men at Hospital das Clínicas in São Paulo, presented at the 2025 Brazilian Urology Congress, found that the median time from prescription to initiation of abiraterone was five months. During that delay, nearly 40% of patients showed PSA progression, and some developed new metastases. In the private sector, the same therapy typically starts within two weeks.

The cap was designed to contain costs in a system that treats millions of patients with limited resources. But the unintended consequence is that men with aggressive disease are pushed into a castration-resistant state, which is more expensive to treat and associated with worse survival. Some estimates suggest that for every month of delay, the risk of death increases by a small but measurable margin.

How the Cap Works in Practice

State-level oncology centers receive a fixed sum from the federal government each year, based on historical spending and population size. High-cost drugs—including abiraterone, enzalutamide, and newer agents like darolutamide—compete for a share of this pool. When one drug is used heavily, less remains for others. Physicians must submit requests to a central approval board, which can take weeks to review.

Because the cap is applied per patient per year, a hospital that treats a large number of men with prostate cancer may hit its limit early in the year. After that, it must either deny new prescriptions or seek emergency funding from the state. The process is opaque and variable across regions; some states have faster approval times than others, creating geographic inequity. For example, centers in São Paulo and Rio de Janeiro often report longer delays than those in smaller states with lower patient volumes, though systematic data are lacking.

For patients who cannot wait, the alternative is bicalutamide, an older nonsteroidal antiandrogen that is much cheaper but less effective in the metastatic setting. Bicalutamide does not require special approval and is often started as a bridge therapy. However, it does not halt disease progression as effectively as the newer agents, and many men eventually require chemotherapy with docetaxel, which carries higher toxicity. A trade-off emerges: using bicalutamide as a placeholder may provide a psychological benefit to patients who feel they are receiving treatment, but it does little to alter the underlying disease trajectory.

The lack of a transparent wait-time guarantee means that patients and families are left in the dark. Advocacy groups have called for public reporting of wait times by hospital, but the Ministry of Health has not yet implemented such a system. Some physicians privately advise patients to seek care in the private sector if they can afford it, widening the gap between rich and poor. This two-tier reality undermines the principle of equity that the SUS was built upon.

Evidence of Delay from São Paulo Cohort

The Hospital das Clínicas cohort, led by oncologist Dr. Ana Lucia de Oliveira, tracked 1,200 men diagnosed with metastatic castration-sensitive prostate cancer between 2020 and 2024. All were prescribed abiraterone or enzalutamide as first-line therapy through the SUS. The median time from prescription to first dose was 5.2 months, with an interquartile range of 3.1 to 7.8 months.

During the waiting period, 38% of patients experienced PSA progression, defined as a rise of at least 25% from nadir. Imaging studies revealed new bone or visceral metastases in 12% of those who had scans. By the time therapy started, roughly one in five men had already developed castration-resistant disease, meaning their cancer no longer responded to androgen deprivation alone. These numbers highlight the tangible harm caused by administrative delays.

For comparison, the same hospital’s private-sector patients started therapy within a median of 14 days. The disparity is stark and reflects the structural limits of the SUS budget. Dr. Oliveira presented these findings at the 2025 Brazilian Urology Congress, calling for an urgent review of the cap policy. The data have not yet been published in a peer-reviewed journal, but they align with anecdotal reports from other large centers.

Critics note that the cohort is from a single, high-volume academic hospital and may not represent the entire country. However, similar patterns have been observed in hospitals in Rio de Janeiro and Belo Horizonte, suggesting the problem is widespread. The Ministry of Health has not released national data on wait times for cancer drugs, citing administrative complexity. Some experts argue that without national-level data, it is difficult to gauge the full scale of the problem or to target interventions effectively.

Clinical Consequences of Late Initiation

When prostate cancer progresses to a castration-resistant state before modern therapy begins, the treatment landscape narrows. Patients who start abiraterone or enzalutamide after castration resistance has set in have lower response rates—roughly 30–40% versus 60–70% in the castration-sensitive setting. They are also more likely to require chemotherapy, with its attendant side effects of fatigue, neuropathy, and infection risk. The clinical trajectory becomes more aggressive, and the window for effective intervention shrinks.

The downstream costs of delayed therapy can offset the upfront savings from the cap. A modeling study by the Brazilian Society of Clinical Oncology estimated that each month of delay increases total treatment costs by approximately 8–12%, primarily due to higher rates of hospitalization, salvage chemotherapy, and palliative care. Some analyses suggest that the cap may actually increase overall spending over a two-year horizon, a counterintuitive outcome that policymakers have been slow to acknowledge.

The World Health Organization has noted that avoidable delays in cancer care contribute to excess mortality, particularly in low- and middle-income countries. For prostate cancer, a modeling exercise by WHO’s International Agency for Research on Cancer estimated that a six-month delay in first-line therapy could increase five-year mortality by 15–20% in the metastatic setting. While these estimates are uncertain, they underscore the stakes. A counter-argument is that some patients with indolent disease may not be harmed by a short delay, but the challenge lies in identifying who can safely wait.

Patients who survive longer after delayed therapy often face a lower quality of life, with more pain, fatigue, and dependence on caregivers. The psychological toll of waiting—knowing that cancer is advancing while the health system stalls—is another burden that is rarely quantified. Support groups in Brazil have begun documenting these experiences through patient-reported outcome surveys, revealing high levels of anxiety and a sense of abandonment. These qualitative data add a human dimension to the statistical evidence.

Policymakers Weigh Reform Options

The Ministry of Health has piloted risk-sharing agreements with manufacturers of abiraterone and enzalutamide. Under these models, the government pays a discounted price only if the drug is initiated within a specified timeframe—say, 30 days of prescription. If delays occur, the manufacturer bears part of the cost. Early results from a pilot in three states show reduced wait times, but the program has not been scaled nationally. One barrier is that manufacturers are reluctant to participate in schemes that could penalize them for system inefficiencies beyond their control.

Another proposal is to create a separate fund for high-cost oncology drugs, ring-fenced from the general cancer budget. This would prevent competition with cheaper therapies and ensure that money allocated for expensive drugs is not diverted elsewhere. However, the proposal has stalled in Congress amid debates over overall health spending and fiscal austerity. Critics argue that a separate fund could reduce flexibility and that the real problem is insufficient total funding, not allocation.

Advocacy groups like the Brazilian Prostate Cancer Alliance have pushed for a transparent, real-time wait-list system. They argue that public reporting of wait times by hospital would create accountability and allow patients to choose facilities with shorter delays. The Ministry has cited technical challenges, including the need for interoperable electronic health records across thousands of clinics. Yet similar systems exist for organ transplants and elective surgeries, suggesting that the obstacles are not insurmountable.

Some health economists argue that the cap itself is not the problem but rather the lack of a prioritization system based on clinical urgency. They propose using a scoring tool that incorporates PSA level, Gleason score, and metastatic burden to rank patients. Those with the most aggressive disease would receive drugs first, while those with slower-growing tumors could safely wait for the next budget cycle. A pilot at Hospital das Clínicas has shown that such a tool can reduce the median wait time for high-urgency patients by about 40%, but implementation across the SUS would require training and standardization.

What the Cap Means for Other LMICs

Brazil is not alone in facing the tension between budget caps and timely access to high-cost cancer drugs. Mexico’s Seguro Popular and India’s Ayushman Bharat both impose similar ceilings, and clinicians in those countries report analogous delays. Prostate cancer incidence is rising in middle-income regions due to aging populations and improved diagnostic capabilities, making the issue more pressing. For example, a study from Mexico City found that patients waited an average of four months for abiraterone under the public system, with similar rates of progression.

Nigeria, which has no public insurance for most cancer drugs, represents an even starker case. Patients must pay out of pocket, and many cannot afford abiraterone at all. Brazil’s experience—where the drug is nominally available but rationed—may be more relevant for countries that have some public coverage but struggle with implementation. The Nigerian example also highlights that caps are a second-best problem; the first-best would be adequate funding and procurement.

The WHO’s prequalification program for generic oncology drugs could lower the cost of abiraterone and enzalutamide, making caps less necessary. Generic versions of abiraterone are already available in India and are being considered for WHO prequalification. If prices drop by 50–70%, as has happened with other cancer generics, the budget pressure in Brazil would ease significantly. However, generic entry alone will not solve delays if the cap remains fixed in nominal terms, because hospitals may still exhaust their budgets if volumes increase.

International organizations like the Union for International Cancer Control have called for real-time monitoring of access delays as a core indicator of health system performance. Brazil’s failure to track wait times nationally is a missed opportunity to generate evidence that could inform policy in other settings. Without data, it is difficult to know whether reforms are working. Some researchers have proposed using pharmacy dispensing records as a proxy for wait times, but privacy concerns and fragmented data systems pose hurdles.

Toward Equitable Access Within Fixed Budgets

Risk-pooling across multiple cancer types could smooth out the volatility in spending on high-cost drugs. If the budget is shared among many hospitals, a single facility that treats a cluster of prostate cancer patients one year does not exhaust its own allocation. Some states in Brazil have experimented with this approach, but national coordination remains weak. A regional pooling arrangement in the state of Minas Gerais showed a 15% reduction in average wait times over two years, but the gains were not sustained due to turnover in health secretariat leadership.

Prioritization based on clinical urgency scoring—similar to how organ transplant waiting lists work—could ensure that the sickest patients receive drugs first. This would require a standardized assessment tool integrated into electronic prescription systems. A pilot at Hospital das Clínicas has shown that such a tool can reduce the median wait time for high-urgency patients by about 40%. However, critics worry that scoring systems may be manipulated or that they could disadvantage patients with less aggressive disease who still need timely therapy.

Electronic prescription tracking, already used in some private clinics, could be extended to the SUS. This would allow real-time visibility of how many patients are waiting for each drug and how long they have been waiting. The Ministry of Health has a digital platform for other purposes, but it has not yet been adapted for cancer drug access. A phased rollout starting with the largest oncology centers could provide proof of concept, but funding for IT infrastructure remains a barrier.

Phased removal of the cap for first-line therapies—starting with the most cost-effective agents—could be a pragmatic step. The Ministry could negotiate lower prices with manufacturers in exchange for a guaranteed volume of purchases, as is done in some European countries. Advocacy groups have urged the government to move faster, but budget constraints and political inertia remain formidable. A gradual approach might allow policymakers to evaluate the impact on spending and outcomes before committing to broader changes.

Ultimately, the Brazilian experience shows that access delays are not inevitable. They are a product of policy design—and can be redesigned. However, any solution must balance fiscal reality with clinical need, and reasonable people disagree on where that balance lies. What is clear is that the current system is failing men with prostate cancer, and the evidence of harm is mounting. The next steps require political will, transparent data, and a willingness to learn from both successes and failures in other health systems.

This article is for informational purposes only and does not constitute medical advice. Patients should consult their healthcare provider for treatment decisions.